Last reviewed · How we verify
NCT04285125: HAM
High Resolution Imaging for Analysis of MVNT
trial testing cerebral MRI in Benign Neuronal Desease in 33 participants. Currently enrolling.
19 May 2025
Quick facts
| Lead sponsor | Fondation Ophtalmologique Adolphe de Rothschild |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 33 |
| Start date | 5 March 2020 |
| Primary completion | 19 May 2025 |
| Estimated completion | 19 May 2027 |
| Sites | 7 locations across France |
Drugs / interventions tested
- cerebral MRI
Conditions studied
- Benign Neuronal Desease — all drugs for Benign Neuronal Desease →
Sponsor
Fondation Ophtalmologique Adolphe de Rothschild — full company profile →
Who can join
18 and older, any sex, with Benign Neuronal Desease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
MVNT (multinodular and vacuolating neuronal tumor of the cerebrum) is a benign, recently discovered, neuronal lesion, the incidence of which is unknown. It seems to predominate in the temporal lobes and presents a characteristic MRI appearance: multiple subcortical nodules, developed at the white substance / gray substance junction, of variable size, well limited, in iso-hyposignal T1, hypersignal T2 and hypersignal FLAIR. The articles describing this entity report the lack of scalability in MRI during patient monitoring, going in the direction of the benignity of the lesion. The diagnosis sometimes remains uncertain with current MRI sequences, and the patient risks undergoing invasive surgery to remove a lesion that is actually benign. Hence the importance of developing the most precise diagnostic criteria possible. The contribution of advanced MRI techniques, such as ultra-high resolution sequences in the characterization of these lesions, has not yet been studied.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04285125
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of cerebral MRI
Trials testing the same drug.
- NCT04705870 — Comparison of the Performance of an Optimized 3D EPI SWI Sequence and a Non-EPI QSM SWI Sequence in Detecting the Centra · completed
- NCT04103190 — Multiparametric Imaging for Analysis of MVNT (Multinodular and Vacuolating Neuronal Tumor) · completed
- NCT02669056 — Brainstem and Prematurity · NA · completed
Other Fondation Ophtalmologique Adolphe de Rothschild trials
Trials by the same sponsor.
- NCT04701619 — Immuno-inflammatory Profile and Response to Ischemic Stroke Reperfusion Therapies (IMMUNOSTROKE) · NA · not yet recruiting
- NCT04763161 — Immuno-inflammation in the Acute Phase of an Ischaemic Cerebral Accident Managed by Decompressive Hemicraniectomy: a Cas · not yet recruiting
- NCT06264531 — Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous M · Phase 2, PHASE3 · recruiting
- NCT06895044 — Evolution of Ocular Growth in Myopic Children: A Prospective Cohort Study · recruiting
- NCT06644196 — Creation of a Database of Images of the Eye With the Holographic Doppler Laser · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04285125 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fondation Ophtalmologique Adolphe de Rothschild
- Last refreshed: 5 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04285125.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing